2,365.00
-30.00 (-1.25%)
| Previous Close | 2,395.00 |
| Open | 2,382.86 |
| Volume | 43,498 |
| Avg. Volume (3M) | 146,302 |
| Market Cap | 1,628,341,248 |
| Price / Earnings (TTM) | 81.55 |
| Price / Earnings (Forward) | 29.15 |
| Price / Sales | 2.57 |
| Price / Book | 3.61 |
| 52 Weeks Range | |
| Earnings Date | 3 Sep 2025 - 8 Sep 2025 |
| TTM Dividend Yield | 0.01% |
| Profit Margin | -0.60% |
| Operating Margin (TTM) | 10.23% |
| Diluted EPS (TTM) | -0.060 |
| Quarterly Revenue Growth (YOY) | 0.80% |
| Quarterly Earnings Growth (YOY) | -88.10% |
| Total Debt/Equity (MRQ) | 57.63% |
| Current Ratio (MRQ) | 1.94 |
| Operating Cash Flow (TTM) | 49.30 M |
| Levered Free Cash Flow (TTM) | 89.54 M |
| Return on Assets (TTM) | 3.81% |
| Return on Equity (TTM) | -1.17% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (GB) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | GENUS PLC ORD 10P | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 4.0 |
| Average | 0.75 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| GENUS PLC ORD 10P | 2 B | 0.01% | 81.55 | 3.61 |
| PHARMA MAR SA PHARMA MAR ORD SH | 16 B | 1.08% | 14.69 | - |
| ARROWHEAD PHARMACEUTICALS INC A | 4 B | - | - | - |
| BASILEA PHARMACEUTICA AG BASILE | 511 M | - | - | 6.18 |
| AVACTA GROUP PLC ORD 10P | 353 M | - | - | 2.35 |
| PROTHENA CORPORATION PLC PROTHE | 330 M | - | 7.53 | - |
|
Genus PLC is a biotechnology company that develops animal genetics for agricultural purposes. The company breeds and distributes the genes of pigs and bulls, scientifically selecting livestock whose offspring are designed to increase the profitability of its customers. In the porcine market, Genus sells boars and sows that produce offspring with desirable characteristics, such as feed-efficient growth or leaner meat. In the dairy and beef markets, the company's primary product is bull semen, which is delivered through artificial insemination to improve its customers' herds and their efficiency. Genus also offers embryos through its subsidiary IVB. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.75% |
| % Held by Institutions | 87.92% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |